(19) World Intellectual Property Organization International Bureau



| 1998 | 1999 | 1994 | 1994 | 1994 | 1994 | 1995 | 1996 | 1996 | 1996 | 1996 | 1996 | 1996 | 1996 | 1996 | 199

(43) International Publication Date 11 August 2005 (11.08.2005)

PCT

(10) International Publication Number WO 2005/072270 A3

- (51) International Patent Classification⁷: C12N 15/00, 15/06, 15/07, G01N 33/20
- A61K 38/00,
- (21) International Application Number:

PCT/US2005/002023

- (22) International Filing Date: 21 January 2005 (21.01.2005)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/538,718

23 January 2004 (23.01.2004) US

- (71) Applicants (for all designated States except US): THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND [US/US]; 1430 Tulane Avenue, New Orleans, LA 70112 (US). XAVIER UNIVERSITY OF LOUISIANA [US/US]; 1 Drexel Drive, New Orleans, LA 70125-1098 (US). INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) [FR/FR]; 101, rue de Tolbiac, F-75654 Paris 13 (FR).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): KLASSEN, Bryan [US/US]; 2100 Sawmill Road, New Orleans, LA 70123-5902 (US). VERROUST, Pierre, J. [FR/FR]; Hôpital Tenon (FR). ALLEN, Patricia [US/US]; 2401 Comet Street, New Orleans, LA 70131 (US). HAM-MOND, Timothy [US/US]; 1418 Bordeaux Street, New Orleans, LA 70115 (US).

- (74) Agents: BAK, Mary, E. et al.; Howson and Howson, Spring House Corporate Center, P.O. Box 457 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CII, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GII, GM, IIR, IIU, ID, IL, IN, IS, IP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GII, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report:
 29 December 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHODS AND COMPOSITONS FOR TREATING CANCER

(57) Abstract: Pharmaceutical compositions, kits and methods useful for the treatment of cancer include a composition containing a modified metallothionein (MT) amino acid sequence or fragment thereof that binds the megalin receptor less avidly than naturally-occuring metallothionein. The modified metallothionein can be in a conjugate with multiple molecules of a therapeutic divalent metal ion. Embodiments of the modified metallothionein complex can bave a negative or neutral charge or a size greater than 70kD. Such compositions are useful also in methods for treating heavy metal poisoning and inhibiting renal uptake of therapeutic divalent metal ions.



(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 11 August 2005 (11.08.2005)

PCT

(10) International Publication Number WO 2005/072270 A2

(51) International Patent Classification:

Not classified

(21) International Application Number:

PCT/US2005/002023

(22) International Filing Date: 21 January 2005 (21.01.2005)

(25) Filing Language:

English

(26) Publication Language:

Linglish

(30) Priority Data: 60/538,718

23 January 2004 (23.01.2004) US

- (71) Applicants (for all designated States except US): THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND [US/US]; 1430 Tulane Avenue, New Orleans, LA 70112 (US). XAVIER UNIVERSITY OF LOUISIANA [US/US]; 1 Drexel Drive, New Orleans, LA 70125-1098 (US). INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) [IR/IR]; 101, rue de Tolbiac, I-75654 Paris 13 (FR).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): KLASSEN, Bryan [US/US]; 2100 Sawmill Road, New Orleans, LA 70123-5902 (US). VERROUST, Pierre, J. [FR/FR]; Hôpital Tenon (FR). ALLEN, Patricla [US/US]; 2401 Comet Street, New Orleans, LA 70131 (US). HAM-MOND, Timothy [US/US]; 1418 Bordeaux Street, New Orleans, LA 70115 (US).

- (74) Agents: BAK, Mary, E. et al.; Howson and Howson, Spring House Corporate Center, P.O. Box 457 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GII, GM, IIR, IIU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PII, PI, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

 without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHODS AND COMPOSITONS FOR TREATING CANCER

(57) Abstract: Pharmaceutical compositions, kits and methods useful for the treatment of cancer include a composition containing a modified metallothionein (MT) amino acid sequence or fragment thereof that binds the megalin receptor less avidly than naturally-occuring metallothionein. The modified metallothionein can be in a conjugate with multiple molecules of a therapeutic divalent metal ion. Embodiments of the modified metallothionein complex can bave a negative or neutral charge or a size greater than 70kD. Such compositions are useful also in methods for treating heavy metal poisoning and inhibiting renal uptake of therapeutic divalent metal ions.

